Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Cipla
UBS
Fish and Richardson
Covington
Queensland Health
US Department of Justice
Accenture
Merck
Cantor Fitzgerald

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,700,645

« Back to Dashboard

Which drugs does patent 7,700,645 protect, and when does it expire?

Patent 7,700,645 protects PREZISTA and PREZCOBIX and is included in three NDAs.

Protection for PREZISTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
Summary for Patent: 7,700,645
Title:Pseudopolymorphic forms of a HIV protease inhibitor
Abstract:New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sul- fonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed.
Inventor(s): Vermeersch; Hans Wim Pieter (Ghent, BE), Thone; Daniel Joseph Christiaan (Beerse, BE), Janssens; Luc Donne Marie-Louise (Malle, BE)
Assignee: Tibotec Pharmaceuticals Ltd. (Little Island, Co. Cork, IE)
Application Number:10/514,352
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,700,645

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Prods PREZISTA darunavir ethanolate SUSPENSION;ORAL 202895-001 Dec 16, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Prods PREZCOBIX cobicistat; darunavir ethanolate TABLET;ORAL 205395-001 Jan 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Prods PREZISTA darunavir ethanolate TABLET;ORAL 021976-004 Dec 18, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Prods PREZISTA darunavir ethanolate TABLET;ORAL 021976-005 Dec 18, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Prods PREZISTA darunavir ethanolate TABLET;ORAL 021976-001 Jun 23, 2006 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Prods PREZISTA darunavir ethanolate TABLET;ORAL 021976-003 Oct 21, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Prods PREZISTA darunavir ethanolate TABLET;ORAL 021976-002 Feb 25, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Janssen Prods PREZISTA darunavir ethanolate TABLET;ORAL 021976-006 Nov 9, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,700,645

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02076929May 16, 2002
PCT Information
PCT FiledMay 16, 2003PCT Application Number:PCT/EP03/50176
PCT Publication Date:December 24, 2003PCT Publication Number: WO03/106461

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Citi
Healthtrust
Chinese Patent Office
Queensland Health
Harvard Business School
Johnson and Johnson
Novartis
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot